GLP-1受体激动剂及其类似物在糖尿病肾病治疗中的研究进展  

Research Progress of GLP-1 Receptor Agonists and Its Analogues in Treatment of Diabetic Kidney Disease

作　　者：储帆 丁国华[1] CHU Fan;DING Guohua(Department of Nephrology,Renmin Hospital of Wuhan University,Wuhan 430060,China)

机构地区：[1]武汉大学人民医院肾内科,武汉430060

出　　处：《医学综述》2023年第19期3890-3896,共7页Medical Recapitulate

基　　金：国家自然科学基金(81770687)。

摘　　要：糖尿病肾病是糖尿病患者的主要微血管并发症,也是最常见的继发性肾小球疾病,控制高危因素可以有效降低终末期肾病的发生风险。胰高血糖素样肽-1受体激动剂(GLP-1RAs)是一种新型降糖药物,它通过延长胰高血糖素样肽-1的半衰期减少胰高血糖素分泌、延迟胃排空,从而发挥降糖、减重作用,并在降低蛋白尿和肾脏不良事件方面具有优势,但其存在不良反应。目前,多种剂型的GLP-1RAs应用于临床治疗,且临床根据患者不同情况选择合适的剂型。未来,进一步研究GLP-1RAs的肾脏保护机制将为研发更安全有效的药物提供思路。Diabetic nephropathy is the main microvascular complication of diabetic patients,and also the most common secondary glomerular disease.Control of high-risk factors can effectively reduce the risk of end-stage nephropathy.Glucagon-like peptide-1 receptor agonists(GLP-1RAs)is a new type of hypoglycemic drug,which reduces glucagon secretion and delays gastric emptying by prolongating the half-life of glucagon-like peptide-1,thereby exerting hypoglycemic and weight loss effects,and has advantages in reducing proteinuria and adverse renal events,although it has adverse effects.At present,a variety of dosage forms of GLP-1RAs are used in clinical treatment,and the appropriate dosage forms are selected according to the different patient conditions.In the future,further research on the renal protection mechanism of GLP-1RAs will provide ideas for the development of safer and more effective drugs.

关 键 词：糖尿病肾病 胰高血糖素样肽-1 胰高血糖素样肽受体激动剂 

分 类 号：R587.1[医药卫生—内分泌] R587.2[医药卫生—内科学]